Table 2.
Best overall response, and ORR and CRR among patients receiving parsaclisib by IRC review (cohort 2)
| Response | WG (n = 28) | DG (n = 72) | All treated patients (N = 100) |
|---|---|---|---|
| Best overall response, n (%) | |||
| CR | 3 (10.7) | 3 (4.2) | 6 (6.0) |
| PR | 13 (46.4) | 39 (54.2) | 52 (52.0) |
| Stable disease | 7 (25.0) | 22 (30.6) | 29 (29.0) |
| Progressive disease | 2 (7.1) | 0 | 2 (2.0) |
| Not evaluable/assessed∗ | 3 (10.7) | 8 (11.1) | 11 (11.0) |
| ORR, % (95% CI) | 57.1 (37.2-75.5) | 58.3 (46.1-69.8) | 58.0 (47.7-67.8) |
| CRR, % (95% CI) | 10.7 (2.3-28.2) | 4.2 (0.9-11.7) | 6.0 (2.2-12.6) |
CRR, complete response rate.
∗
Two patients in the WG and 2 patients in the DG (4 total overall) were not evaluable owing to no disease per IRC in 3 patients, and insufficient anatomical coverage per IRC in 1 patient; 1 patient in the WG and 6 patients in the DG (7 total overall) did not have postbaseline measurement and could not be assessed.